Stoke Therapeutics (STOK) Assets Average (2019 - 2026)
Stoke Therapeutics (STOK) posted quarterly Assets Average of $430.9 million for Q1 2026, up 27.01% year-over-year from $339.2 million in Q1 2025, and up 10.66% quarter-over-quarter from $389.3 million in Q4 2025.
Stoke Therapeutics (STOK) Assets Average (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $430.9 million for Q1 2026.
- In Q1 2026, Assets Average rose 27.01% year-over-year to $430.9 million; the TTM figure through Mar 2026 stood at $430.9 million (up 27.01% YoY), while the FY2025 annual figure was $345.0 million, up 38.03% from the prior year.
- Assets Average for Q1 2026 stood at $430.9 million, up from $389.3 million in the prior quarter.
- The five-year high for Assets Average was $430.9 million in Q1 2026, with the low at $216.8 million in Q1 2024.
- The 5-year median for Assets Average is $282.4 million (2024), against an average of $302.8 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average retreated 19.4% in 2024, then soared 56.49% in 2025.
- Stoke Therapeutics' Assets Average stood at $266.8 million in 2022, then declined by 12.27% to $234.1 million in 2023, then rose by 20.64% to $282.4 million in 2024, then soared by 37.85% to $389.3 million in 2025, then climbed by 10.66% to $430.9 million in 2026.
- Business Quant data shows STOK's Assets Average at $430.9 million in Q1 2026, $389.3 million in Q4 2025, and $372.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 418.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 418.62 Mn |
| Mar 31, 2026 | 430.86 Mn |
| Dec 31, 2025 | 389.35 Mn |
| Sep 30, 2025 | 372.39 Mn |
| Jun 30, 2025 | 395.70 Mn |
| Mar 31, 2025 | 339.22 Mn |
| Dec 31, 2024 | 282.44 Mn |
| Sep 30, 2024 | 300.54 Mn |
| Jun 30, 2024 | 256.47 Mn |
| Mar 31, 2024 | 216.76 Mn |
| Dec 31, 2023 | 234.12 Mn |
| Sep 30, 2023 | 248.40 Mn |
| Jun 30, 2023 | 269.36 Mn |
| Mar 31, 2023 | 268.93 Mn |
| Dec 31, 2022 | 266.85 Mn |
| Sep 30, 2022 | 289.53 Mn |
| Jun 30, 2022 | 308.68 Mn |
| Mar 31, 2022 | 277.40 Mn |
| Dec 31, 2021 | 246.32 Mn |
| Sep 30, 2021 | 259.11 Mn |